Targeting TGF-β Signaling for Fibrosis and Cancer Therapy
노바스템
2024-04-18
조회수 413
This review by Peng et al. delves deeply into the biological significance and therapeutic potential of Transforming Growth Factor Beta (TGF-β) in fibrosis and cancer, illustrating its paradoxical roles across different stages of disease progression. The study provides a comprehensive overview of TGF-β's involvement in cell signaling pathways that regulate cellular proliferation, differentiation, and apoptosis. TGF-β is intricately involved in epithelial-mesenchymal transition (EMT), a process pivotal for fibrosis and metastasis in cancers. In the context of fibrosis, TGF-β promotes the deposition of the extracellular matrix, contributing to tissue scarring and organ dysfunction. In cancer, its role is bifurcated; it suppresses tumor growth in early stages by inhibiting cell cycle progression, yet later promotes tumor invasiveness and immune evasion by altering the tumor microenvironment. The paper emphasizes the clinical implications of targeting TGF-β signaling pathways with therapeutic interventions such as inhibitors, monoclonal antibodies, and combination therapies, aiming to disrupt the complex network of TGF-β-mediated signaling in disease pathology.
The detailed exploration of TGF-β in regulating cell functions and its implications in fibrosis and various cancers reflects its potential synergy with Novastem's stem cell therapy. Like TGF-β's role in cellular homeostasis and pathological transformation, stem cell therapies may offer similar dual functionality in regenerative and reparative applications in conditions such as fibrosis and cancer.
Dual Roles: TGF-β acts as both a tumor suppressor and promoter, making it a key target for therapeutic strategies.
Mechanisms of Action: The signaling pathways of TGF-β, including SMAD and non-SMAD pathways, play crucial roles in its function.
Therapeutic Implications: Understanding TGF-β's mechanisms can lead to more effective treatments for diseases like fibrosis and cancer where TGF-β plays a central role.
This review by Peng et al. delves deeply into the biological significance and therapeutic potential of Transforming Growth Factor Beta (TGF-β) in fibrosis and cancer, illustrating its paradoxical roles across different stages of disease progression. The study provides a comprehensive overview of TGF-β's involvement in cell signaling pathways that regulate cellular proliferation, differentiation, and apoptosis. TGF-β is intricately involved in epithelial-mesenchymal transition (EMT), a process pivotal for fibrosis and metastasis in cancers. In the context of fibrosis, TGF-β promotes the deposition of the extracellular matrix, contributing to tissue scarring and organ dysfunction. In cancer, its role is bifurcated; it suppresses tumor growth in early stages by inhibiting cell cycle progression, yet later promotes tumor invasiveness and immune evasion by altering the tumor microenvironment. The paper emphasizes the clinical implications of targeting TGF-β signaling pathways with therapeutic interventions such as inhibitors, monoclonal antibodies, and combination therapies, aiming to disrupt the complex network of TGF-β-mediated signaling in disease pathology.
The detailed exploration of TGF-β in regulating cell functions and its implications in fibrosis and various cancers reflects its potential synergy with Novastem's stem cell therapy. Like TGF-β's role in cellular homeostasis and pathological transformation, stem cell therapies may offer similar dual functionality in regenerative and reparative applications in conditions such as fibrosis and cancer.
#TGFβ #Fibrosis #CancerTherapy #EpithelialMesenchymalTransition #CellSignaling #StemCellTherapy